Aytu BioPharma reported a decline in revenue and a net loss in fiscal Q2 2026 as the company increased investment to support the commercial launch of EXXUA, partially offset by stable performance in its ADHD portfolio.

Aytu BioPharma's Q4 showed stable revenue and flat adjusted EBITDA, but the quarter ended with a larger net loss driven by impairment charges and derivative warrant liabilities linked to the upcoming EXXUA launch.

Aytu BioPharma achieved 32% revenue growth year-over-year in Q3 2025, driven by robust performance in both its ADHD and Pediatric portfolios. The company reported net income of $4.0 million and adjusted EBITDA of $3.9 million, reflecting successful execution of its strategic realignment and cost optimization efforts.

Aytu BioPharma reported a net income of $0.8 million and adjusted EBITDA of $1.3 million for the second quarter of fiscal 2025. The company saw an 86% sequential increase in Pediatric Portfolio net revenue and a 16% sequential increase in ADHD Portfolio net revenue, marking the first quarterly sequential prescription increase for both portfolios since Q2 fiscal 2023.

Aytu BioPharma reported a net income of $1.5 million and an adjusted EBITDA of $1.9 million for the first quarter of fiscal year 2025. The company's ADHD portfolio net revenue increased by 1% year-over-year, while the Pediatric Portfolio net revenue increased 54% sequentially. The company is implementing organizational changes and an operating optimization plan to further streamline operations and reduce expenses.

Aytu BioScience reported Q4 2024 consolidated net revenue of $18.0 million compared to $30.7 million in the prior year period. The company's net loss was $4.6 million, or $0.82 net loss per share, compared to a net loss of $2.5 million, or $0.59 net loss per share, in Q4 2023. Consolidated adjusted EBITDA was $1.5 million in Q4 2024, compared to $7.7 million in Q4 2023.

Aytu BioPharma reported Q3 2024 consolidated net revenue of $18.0 million. The ADHD Portfolio net revenue increased by 49% to $12.3 million. The company's net loss was $2.9 million, or $0.52 per share, and consolidated adjusted EBITDA was positive $0.4 million.

Aytu BioScience, Inc. reported a net revenue of $22.9 million for Q2 2024, with operating income reaching $2.4 million, marking the company's first quarter of positive operating income. The ADHD Portfolio revenue increased by 49% year-over-year to $16.6 million. Net loss for the quarter was $0.2 million, or $0.04 per share.

Aytu BioPharma reported a decrease in total net revenue to $22.1 million compared to $27.7 million in the previous year, primarily due to the wind down of the Consumer Health segment. The Rx segment's net revenue was $17.8 million, with ADHD product revenue increasing by 31%. The company reported a net loss of $8.1 million, impacted by a $5.9 million loss on derivative warrant liabilities.

Aytu BioPharma reported a strong Q4 2023 with record revenues of $30.7 million, a 12% increase year-over-year, and a positive Adjusted EBITDA of $7.7 million. The company's Rx segment drove growth with record prescriptions and revenues, while the Consumer Health segment is being de-emphasized to improve profitability. Aytu is focusing on its core Rx segment and expects to achieve net income going forward.

Aytu BioPharma reported a decrease in revenue of 6% year-over-year, with total net revenue at $22.7 million. Despite the revenue decrease, total prescriptions increased by 32% compared to Q3 2022. The company reported a net loss of $7.2 million, or $1.93 per share, compared to a net loss of $53.3 million, or $35.90 per share, in Q3 2022. Gross margins improved to 56% compared to 52% in the year-ago quarter.

Aytu BioPharma reported a 14% increase in total net revenue to $26.3 million, driven by a 23% growth in the Rx segment, and achieved its second consecutive quarter of positive Adjusted EBITDA at $0.7 million. The company's strategic shift to focus on commercial business growth and cost reductions contributed to improved profitability.

Aytu BioPharma reported a record quarterly revenue of $27.7 million, driven by a 34% growth in the Rx segment, and achieved a positive adjusted EBITDA of $1.4 million.

Aytu BioPharma reported record fourth quarter revenue of $27.4 million, a 17% increase year-over-year, driven by a 28% increase in prescription product revenue. The company's Prescription segment achieved positive adjusted EBITDA, while the Consumer Health segment experienced a slight revenue decrease due to supply chain disruptions.

Aytu BioPharma reported a 79% year-over-year increase in net revenue to $24.2 million for the third quarter of fiscal year 2022, marking the highest revenue in the company's history. The company's strategic priorities are focused on driving revenue growth, increasing financial efficiencies, and advancing its pipeline of therapeutics.

Aytu BioPharma reported a net revenue of $23.1 million for the second quarter of fiscal year 2022, a 53% increase compared to the same quarter in fiscal year 2021. The company's prescription sales grew by over 103% year-over-year, and the consumer health division saw a growth of over 7%. The net loss for the quarter was $11.5 million, or $0.44 per share.

Aytu BioPharma reported strong Q1 2022 financial results, with net revenues increasing by 62% to $21.9 million compared to the same quarter last year. The company's prescription and consumer health product revenues grew organically, and its late-stage development pipeline advanced toward key milestones. The company ended the quarter with $40.6 million in cash, cash equivalents and restricted cash.

Aytu BioPharma reported a net revenue of $23.5 million for the fourth quarter of fiscal year 2021, marking a 138% increase compared to the same quarter in the previous year. The company's net loss for the quarter was $19 million, or $0.81 per share. Aytu also focused on integrating its sales forces and patient access programs following the merger with Neos Therapeutics.

Aytu BioPharma reported a net revenue of $13.5 million for Q3 2021, compared to $8.2 million in the same quarter last year. The company's net loss was $25.5 million, or $1.41 per share, which included Neos merger-related expenses and inventory write-offs.

Aytu BioScience reported a record fiscal Q2 2021 net revenue of $15.1 million, a 377% increase year-over-year. The Consumer Health revenue reached an all-time high of $7.9 million, and the company ended the quarter with $62.3 million in cash, cash equivalents, and restricted cash.

Aytu BioScience reported a substantial increase in net revenue for Q1 2021, reaching $13.5 million, an 839% increase year-over-year. The company reduced its adjusted EBITDA loss to $1.3 million and holds $38.2 million in cash and cash equivalents.

Aytu BioScience reported a strong Q4 2020 with net revenue increasing by 766% year-over-year to $14.9 million. The company's net loss was ($3.1) million, and adjusted EBITDA loss was reduced to $1.7 million. Cash, cash equivalents, and restricted cash stood at $48.3 million.

Aytu BioScience reported a significant increase in revenue for the third quarter of fiscal year 2020, driven by the acquisition of Innovus Pharmaceuticals. The company's cash position was also substantially strengthened through equity offerings and warrant exercises. The company also signed agreements for COVID-19 rapid tests and the Healight technology platform.

Aytu BioScience reported a 77% year-over-year increase in revenue, reaching $3.2 million for the quarter ended December 31, 2019. The net loss significantly decreased by 95% compared to the same quarter of the previous year, amounting to $0.2 million. These results reflect the partial contribution from the Cerecor assets acquired on November 1, 2019.